Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)
NCT ID: NCT00437177
Last Updated: 2009-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
50 participants
INTERVENTIONAL
2007-01-31
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
apomorphine
Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
[(123)I] iodobenzamide
\[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* alcohol dependence length at least 8 years.
* male
* age 25 - 60 years
Exclusion Criteria
* another major axis I psychiatric diagnosis
* comorbid neurological disorder
* comorbid cardiovascular disorder
* comorbid metabolic disorder
* brain injury
* apomorphine allergy
* iode allergy
* diazepam allergy
25 Years
60 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitari Vall d'Hebron Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Servei de Psiquiatria. Hospital Universitari Vall d'Hebron
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Miquel Casas, Prof
Role: PRINCIPAL_INVESTIGATOR
Psychiatry Service, Hospital Universitari Vall d'Hebron
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Psychiatry Service, Hospital Universitari Vall d'Hebron
Barcelona, Catalonia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Miquel Casas, Prof
Role: primary
Xavier Castells
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT: 2004-001893-24
Identifier Type: -
Identifier Source: secondary_id
OH SPECT APO
Identifier Type: -
Identifier Source: org_study_id